Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 195

1.

[Hyperkinetic disorders in childhood and adolescence- an analysis of KinderAGATE 2009-2012].

Stegmann B, Rexroth CA, Wenzel-Seifert K, Haen E.

Z Kinder Jugendpsychiatr Psychother. 2015 Mar;43(2):101-14. German.

PMID:
25951625
2.

Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.

Mikolajczyk R, Horn J, Schmedt N, Langner I, Lindemann C, Garbe E.

JAMA Pediatr. 2015 Apr;169(4):391-5. doi: 10.1001/jamapediatrics.2014.3275.

PMID:
25686215
3.

Correlates of incident bipolar disorder in children and adolescents diagnosed with attention-deficit/hyperactivity disorder.

Jerrell JM, McIntyre RS, Park YM.

J Clin Psychiatry. 2014 Nov;75(11):e1278-83. doi: 10.4088/JCP.14m09046.

PMID:
25470092
4.

Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.

Guertin J, LeLorier J, Durand M, Gow R, Holbrook A, Levine M.

J Popul Ther Clin Pharmacol. 2014;21(3):e357-69. Epub 2014 Oct 8.

5.

Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UK.

Warrer P, Aagaard L, Hansen EH.

Drug Saf. 2014 Oct;37(10):805-13. doi: 10.1007/s40264-014-0215-2.

PMID:
25112669
7.

Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.

Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, Hodgkins P, Civil R, Coghill DR.

CNS Drugs. 2014 Nov;28(11):1059-69. doi: 10.1007/s40263-014-0188-9.

9.

Medical treatment of children and youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study.

Norum J, Olsen AI, Nohr FI, Heyd A, Totth A.

Glob J Health Sci. 2014 Apr 14;6(4):155-62. doi: 10.5539/gjhs.v6n4p155.

10.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Eiland LS, Bell EA, Erramouspe J.

Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Review.

PMID:
24982313
11.

Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study.

Chen Q, Sjölander A, Runeson B, D'Onofrio BM, Lichtenstein P, Larsson H.

BMJ. 2014 Jun 18;348:g3769. doi: 10.1136/bmj.g3769.

12.

Safety of medicines used for ADHD in children: a review of published prospective clinical trials.

Clavenna A, Bonati M.

Arch Dis Child. 2014 Sep;99(9):866-72. doi: 10.1136/archdischild-2013-304170. Epub 2014 Apr 19. Review.

PMID:
24748641
13.

Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.

Husarova V, Bittsansky M, Ondrejka I, Dobrota D.

Psychiatry Res. 2014 Apr 30;222(1-2):75-83. doi: 10.1016/j.pscychresns.2014.03.003. Epub 2014 Mar 15.

PMID:
24679996
14.

Pharmacological and psychosocial treatments for adolescents with ADHD: an updated systematic review of the literature.

Sibley MH, Kuriyan AB, Evans SW, Waxmonsky JG, Smith BH.

Clin Psychol Rev. 2014 Apr;34(3):218-32. doi: 10.1016/j.cpr.2014.02.001. Epub 2014 Feb 27. Review.

PMID:
24632046
15.

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.

Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Review.

PMID:
24627974
16.
17.

Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries.

Altin M, El-Shafei AA, Yu M, Desaiah D, Treuer T, Zavadenko N, Gao HY.

Drugs Context. 2013 Sep 13;2013:212260. doi: 10.7573/dic.212260. eCollection 2013 Sep 13.

18.

What place for lisdexamfetamine in children and adolescents with ADHD?

[No authors listed]

Drug Ther Bull. 2013 Oct;51(10):114-7. doi: 10.1136/dtb.2013.10.0208.

PMID:
24113146
19.

Toward systems neuroscience of shared and distinct neural effects of medications used to treat attention-deficit/hyperactivity disorder.

Castellanos FX, Meyer E.

Biol Psychiatry. 2013 Oct 15;74(8):560-2. doi: 10.1016/j.biopsych.2013.08.021. No abstract available.

PMID:
24075492
20.

Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.

Germinario EA, Arcieri R, Bonati M, Zuddas A, Masi G, Vella S, Chiarotti F, Panei P; Italian ADHD Regional Reference Centers.

J Child Adolesc Psychopharmacol. 2013 Sep;23(7):440-7. doi: 10.1089/cap.2012.0086. Epub 2013 Sep 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk